Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Invites Manufacturers, Ad Agencies To Discuss DTC Ad Designs

Executive Summary

FDA would like to consult with pharmaceutical companies and their advertising agencies early on in the development of direct-to-consumer advertising campaigns
Advertisement

Related Content

Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill
Celebrex, Bextra Ads Draw Fire From FDA; Reminder Of “Reminder” Ad Rules
FDA External Relations Head Pitts Will Leave Agency For New York PR Firm
Decline In Ad Letters Does Not Signal Leniency By FDA, Agency Says
Rep. Waxman Challenges FDA Contact With Rx Companies On DTC Guides
DTC Risk Information Placement Can Affect Fair Balance, Academic Tells FDA
DTC Battle: PhRMA Should Pay More Attention To Issue, Sen. Craig Says
DTC Battle: PhRMA Should Pay More Attention To Issue, Sen. Craig Says
Berlex Yasmin TV Ad Cited By FDA Following Release In Test Markets
Flonase, Zaditor DTC Ads Cited By FDA; Both Allergy Campaigns Are Over
Advertisement
UsernamePublicRestriction

Register

PS042568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel